The Effects of Cyclosporine on Platelet Function and Cyclooxygenase Expression in Normal Dogs

Journal of Veterinary Internal Medicine

Volumn 26, Issue 6, 2012, Pages 1389-1401

  Thomason, J ^a   Lunsford, K ^a   Stokes, J ^a   Pinchuk, L ^a   Wills, R ^a   Langston, C ^a   Pruett, S ^a   Mackin, A ^a  

^a MISSISSIPPI STATE UNIVERSITY   (United States)

Author keywords

Canine; COX; Immunosuppression; Thromboxane

Indexed keywords

BIOLOGICAL MARKER; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; PADGEM PROTEIN; PHOSPHATIDYLSERINE; THROMBOXANE;

ANIMAL; ARTICLE; DOG; DRUG EFFECT; FEMALE; GENE EXPRESSION REGULATION; METABOLISM; THROMBOCYTE; URINE;

ANIMALS; BIOLOGICAL MARKERS; BLOOD PLATELETS; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOSPORINE; DOGS; FEMALE; GENE EXPRESSION REGULATION; IMMUNOSUPPRESSIVE AGENTS; P-SELECTIN; PHOSPHATIDYLSERINES; THROMBOXANES;

ANIMALIA; CANIS FAMILIARIS;

EID: 84869886882     PISSN: 08916640     EISSN: 19391676     Source Type: Journal    
DOI: 10.1111/j.1939-1676.2012.01025.x     Document Type: Article

References (66)

1. Daigle JC. More economical use of cyclosporine through combination drug therapy. J Am Anim Hosp Assoc 2002;38:205-208.
2. Guaguere E, Steffan J, Cyclosporin T, Olivry A. A new drug in the field of canine dermatology. Vet Dermatol 2004;15:61-74.
3. Hardie RJ, Gregory SP, Tomlin J, et al. Cyclosporine treatment of anal furunculosis in 26 dogs. J Small Anim Pract 2005;46:3-9.
4. O'Neill T, Edwards GA, Holloway S. Efficacy of combined cyclosporine A and ketoconazole treatment of anal furunculosis. J Small Anim Pract 2004;45:238-243.
5. Klein A, Deneuche A, Fayolle P, et al. Preoperative immunosuppressive therapy and surgery as a treatment for anal furunculosis. Vet Surg 2006;35:759-768.
6. Allenspach K, Rufenacht S, Sauter S, et al. Pharmacokinetics and clinical efficacy of cyclosporine treatment in dogs with steroid-refactory inflammatory bowel disease. J Vet Intern Med 2006;20:239-244.
7. Kahan BD. Therapeutic drug monitoring of cyclosporine: 20 years of progress. Transplant Proc 2004;36Suppl2S: 378S-391S.
8. Tomasiak M, Rusak T, Gacko M, et al. Cyclosporine enhances platelet procoagulant activity. Nephrol Dial Transplant 2007;22:1750-1756.
9. Grace A, Barradas M, Mikhailidis D, et al. Cyclosporine A enhances platelet aggregation. Kidney Int 1987;32:889-895.
10. Averna M, Barbagallo C, Ganci A, et al. Determinants of enhanced thromboxane biosynthesis in renal transplantation. Kidney Int 2001;59:1574-1579.
11. Sahin G, Akay O, Kus E, et al. Effects of immunosuppressive drugs on platelet aggregation and soluble P-selectin levels in renal transplant patients. Ren Fail 2009;31:111-7.
12. Reimer ME, Troy GC, Warnick LD. Immune-mediated hemolytic anemia: 70 cases (1988-1996). J Am Anim Hosp Assoc 1999;35:384-391.
13. Carr A, Panciera D, Kidd L. Prognostic factors for mortality and thromboembolism in canine immune-mediated hemolytic anemia: A retrospective study of 72 dogs. J Vet Intern Med 2002;16:504-509.
14. Weiss D, Brazzell J. Detection of activated platelets in dogs with primary immune-mediated hemolytic anemia. J Vet Intern Med 2006;20:682-686.
15. Thomason J, Lunsford K, Mackin A, et al. Effects of cyclosporine on canine platelet procoagulant activity. J Vet Intern Med 2009;23:692.
16. Weber A, Przytulski B, Schumacher M, et al. Flow cytometry analysis of platelet cyclooxygenase-2 expression: induction of platelet cyclooxygenase-2 in patients undergoing coronary artery bypass grafting. Br J Haematol 2002;117:424-426.
17. Zetterberg E, Lundberg L, Palmblad J. Expression of cox-2, tie-2 and glycodelin by megakaryocytes in patients with chronic myeloid leukaemia and polycythaemiavera. Br J Haematol 2003;121:497-499.
18. Thomason J, Lunsford K, Mullins K, et al. Platelet cyclooxygenase expression in normal dogs. J Vet Intern Med 2011;25:1106-1112.
19. Nam H, McAnulty J, Kwak H, et al. Gingival overgrowth in dogs associated with clinically relevant cyclosporine blood levels: observations in a canine renal transplantation model. Vet Surg 2008;37:247-253.
20. Wills TB, Wardrop KJ, Meyers KM. Detection of activated platelets in canine blood by use of flow cytometry. Am J Vet Res 2006;67:56-63.
21. Moritz A, Walcheck BK, Weiss DJ. Flow cytometric detection of activated platelets in the dog. Vet Clin Path 2003;32:6-12.
22. 2 excretion in dogs with gastric dilatation-volvulus. Am J Vet Res 2006;67:78-83.
23. 2 and coagulation activation markers measured within 24 h of human acute ischemic stroke. Neurosci Lett 2001;313:88-92.
24. Callan MB, Giger U. Assessment of a point-of-care instrument for identification of primary hemostatic disorders in dogs. Am J Vet Res 2001;62:652-658.
25. Mischke R, Keidel A. Influence of platelet count, acetylsalicylic acid, vonWillebrand's disease, coagulopathies, and haematocrit on results obtained using a platelet function analyser in dogs. Vet J 2003;165:43-52.
26. Nielsen L, Zois N, Pedersen H, et al. Platelet function in dogs: breed differences and effect of acetylsalicylic acid administration. Vet Clin Pathol 2007;36:267-273.
27. Morales F, Couto C, Iazbik M. Effects of 2 concentrations of sodium citrate on coagulation test results, von Willebrand Factor concentration, and platelet function in dogs. J Vet Intern Med 2007;21:472-475.
28. Brunner E, Puri M. Nonparametric methods in factorial designs. Stat Pap 2001;42:1-52.
29. Shah DA, Madden LV. Nonparametric analysis of ordinal data in designed factorial experiments. Phytopathology 2004;94:33-43.
30. Adamo P, Rylander H, Adams W. Ciclosporin use in multi-drug therapy for meningoencephalomyelitis of unknown aetiology in dogs. J Small Anim Pract 2007;48:486-496.
31. Jespersen B, Thiesson H, Henriksen C, et al. Differential effects of immunosuppressive drugs on COX-2 activity in vitro and in kidney transplant patients in vivo. Nephrol Dial Transplant 2009;24:1644-1655.
32. Braun-Dullaeus R, Feussner M, Walker G, et al. Cyclosporine-induced coronary artery constriction-dissociation between thromboxane release and coronary vasospasm. J Heart Lung Transplant 1999;18:328-335.
33. Gonzalez-Correa J, De La Cruz J, Lucena M, et al. Effect of cyclosporine A on platelet aggregation and thromboxane/prostacyclin balance in a model of extrahepatic cholestasis in the rat. Thromb Res 1996;81:367-381.
34. Hoh C, Smith S, McMichael M, et al. Evaluation of effects of low-dose aspirin administration on urinary thromboxane metabolites in healthy dogs. Am J Vet Res 2011;72:1038-1045.
35. Mullins K, Thomason J, Lunsford K, et al. Effects of carprofen, meloxicam and deracoxib on platelet function in dogs. Vet Anaesth Analg 2012;39:206-217.
36. Perneby C, Granstrom E, Beck O, et al. Optimization of an enzyme immunoassay for 11-dehydro-thromboxane B(2) in urine: Comparison with GC-MS. Thromb Res 1999;96:427-436.
37. 2 production in patients with systemic lupus erythematosus. J Clin Invest 1985;76:1011-1018.
38. Johnson GJ, Leis LA, Rao GHR, White JG. Arachidonate-induced platelet aggregation in the dog. Thromb Res 1979;14:147-154.
39. Johnson GJ, Leis LA, King RA. Thromboxane responsiveness of dog platelets in inherited as an autosomal recessive trait. Thromb Haemostasis 1991;65:578-580.
40. Johnson GJ, Leis LA, Dunlop PC. Thromboxane-insensitive dog platelets have impaired activation of phospholipase C due to receptor-linked G protein dysfunction. J Clin Invest 1993;92:2469-2479.
41. 2, and specific receptor antagonists on vascular smooth muscle cell proliferation. Circulation 1997;96:2280-2286.
42. McAdam B, Catella-Lawson F, Mardini I, et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA 1999;96:272-277.
43. Ruan C, So S. Ruan. Inducible COX-2 dominates over COX-1 in prostacyclin biosynthesis: Mechanisms of COX-2 inhibitor risk to heart disease. Life Sci 2011;88:24-30.
44. Hennan J, Huang J, Barrett T, et al. Effects of selective cyclooxygenase-2 inhibition on vascular responses and thrombosis in canine coronary arteries. Circulation 2001;104:820-825.
45. Hocherl K, Dreher F, Vitzthum H, et al. Cyclosporine A suppresses cyclooxygenase-2 expression in the rat kidney. J Am Soc Nephrol 2002;13:2427-2436.
46. Chiang C, Chen Y, Hung F, et al. Cyclosporin-A inhibits the expression of cyclooxygenase-2 in gingiva. J Periodontal Res 2007;42:443-449.
47. Kay-Mugford P, Benn S, LaMarre J, et al. Cyclooxygenase expression in canine platelets and Mardin-Darby canine kidney cells. Am J Vet Res 2000;61:1512-1516.
48. Yu Y, Cheng Y, Fan J, et al. Differential impact of prostaglandin H synthase 1 knockdown on platelets and parturition. J Clin Invest 2005;115:986-995.
49. Rocca B, Secchiero P, Ciabattoni G, et al. Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. Proc Natl Acad Sci USA 2002;99:7634-7639.
50. ® in patients medicated with acetylsalicylic acid strongly depends on concentration of sodium citrate used for anticoagulation of blood sample. Thromb Res 2000;98:295-299.
51. Balasubramanian K, Mirnikjoo B, Schroit A. Regulated externalization of phosphatidylserine at the cell surface. J Biol Chem 2007;282:18357-18364.
52. Leung R, Gwozdz A, Wang H, et al. Persistence of procoagulant surface expression on activated human platelets: Involvement of apoptosis and aminophospholipid translocase activity. J Thromb Haemost 2007;5:560-570.
53. Leytin V, Allen D, Mutlu A, et al. Mitochondrial control of platelet apoptosis: Effect of cyclosporin A, an inhibitor of the mitochondrial permeability transition pore. Lab Invest 2009;89:374-384.
54. Remenyi G, Szasz R, Friese P, et al. Role of mitochondrial permeability transition pore in coated-platelet formation. Arterioscler Thromb Vasc Biol 2005;25:467-471.
55. Zhang H, Nimmer PM, Tahir SK, et al. Bcl-2 family proteins are essential for platelet survival. Cell Death Differ 2007;14:943-51.
56. Dale G, Friese P. Bax activators potentiate coated-platelet formation. J Thromb Haemost 2006;4:2664-2669.
57. Graff J, Klinkhardt U, Harder S, et al. Immunosuppressive therapy regimen and platelet activation in renal transplant patients. Clin Pharmacol Ther 2002;72:411-418.
58. Berger G, Hartwell D, Wagner D. P-selectin and platelet clearance. Blood 1998;92:4446-4452.
59. Palabrica T, Lobb R, Furie BC, et al. Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent platelets. Nature 1992;359:848-851.
60. Cambien B, Wagner D. A new role in hemostasis for the adhesion receptor P-selectin. Trends Mol Med 2004;10:179-186.
61. Liu Z, Miner J, Yago T, et al. Differential regulation of human and murine P-selectin expression and function in vivo. J Exp Med 2010;207:2975-2987.
62. Weller A, Isenmann S, Vestweber D. Cloning of the mouse endothelial selectins: Expression of both E- and P-selectin is inducible by tumor necrosis factor alpha. J Biol Chem 1992;267:15176-15183.
63. Hahne M, Jager U, Isenmann S, et al. Five tumor necrosis factor-inducible cell adhesion mechanisms on the surface of mouse endothelioma cells mediate the binding of leukocytes. J Cell Biol 1993;121:655-664.
64. Evans S, Giddings J, Muraki T, et al. Expression of von Willebrand Factor, P-selectin (CD62P) and thrombomodulin in human endothelial cells in culture modulated by cyclosporine A. Clin Lab Haematol 1997;19:115-122.
65. Markovic S, Raab M, Daxecker H, et al. In vitro effects of cyclosporine A on the expression of adhesion molecules on human umbilical vein endothelial cells. Clin Chim Acta 2002;316:25-31.
66. Archer T, Fellman C, Stokes J, et al. Pharmacodynamic monitoring of canine T-cell cytokine responses to oral cyclosporine. J Vet Intern Med 2011;25:1391-1397.